Right now, a lot of the arrangements that are made for some of these second-line therapies are that they are being acquired from northern markets and not from generic markets. Many of them are being offered at reduced prices within an environment that protects the patent of those drugs.
What we're looking for in terms of having these being able to be offered and genericized, and mixed and matched as well, is to create ease of therapy, because many of the molecules available today are not co-formulated. You don't have three drugs in one pill.
When you are able to make something generic, make it available, you can then take something from one company that's patented in one company and take something from another company that's patented with the other company and put them together in one pill and make it a lot easier for patients to take.
The other piece is now you are in a more competitive environment as well, because if this formula is repeated through different markets where these compulsory licensing agreements are in place, then we can actually have these components of therapies produced generically and be much cheaper for the end users, to the purchasers.